KOD
NASDAQKodiak Sciences Inc
Price$39.46+1.10 (+2.87%)
01:30 PM07:45 PM
News · 26 weeks34+200%
2026-03-012026-08-23
Mix1790d
- Insider9(53%)
- Other5(29%)
- SEC Filings3(18%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Kodiak Sciences IncSCHEDULE 13G - Kodiak Sciences Inc. (0001468748) (Subject)
- SECSEC Form 10-Q filed by Kodiak Sciences Inc10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial ResultsPALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular Edema Secondary to Inflammation. We comple
- PRKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular EdemaPhase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema (DME). KSI-501 is an investigational, first-in-class bispecific therapy built on Kodiak's ABC® Platform and designed to potently inhibit two complementary pathways implicated in retinal vascular disease
- PRKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 releaseCompletion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline clinical data release anticipated in 2Q 2027PALO ALTO, Calif., Aug. 6, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular edema secondary to inflammation ("MESI"). Kodiak also reaffirmed its plan to release the topline data from Pivotal
- INSIDERSEC Form 4 filed by Chief Financial Officer Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Chairman and CEO Perlroth Victor4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Yang Taiyin4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Profusek Robert4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Levy Richard S4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Dahiyat Bassil I4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Bancroft Charles A4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Bros. Advisors Lp4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- INSIDERChief Financial Officer Borgeson John A. exercised 30,000 shares at a strike of $1.04 and sold $1,023,009 worth of shares (30,000 units at $34.10) as part of a pre-agreed trading plan (SEC Form 4)4 - Kodiak Sciences Inc. (0001468748) (Issuer)
- SECSEC Form 8-K filed by Kodiak Sciences Inc8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences to Present at 2026 Jefferies Global Healthcare ConferencePALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 11:40am ET (8:40am PT). A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.About Kodiak Sciences Inc. Kodiak Sciences (NASDAQ:KOD) is a pr
- ANALYSTKodiak Sciences upgraded by Chardan Capital Markets with a new price targetChardan Capital Markets upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $61.00
- SECSEC Form 10-Q filed by Kodiak Sciences Inc10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
- SECKodiak Sciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kodiak Sciences Inc. (0001468748) (Filer)
- PRKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial ResultsPALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences."The recent positive Phase 3 GLOW2 results for Zenkuda reinforce the strength of our ABC Platform and position us to move forward on our first multi-indication BLA submission. At the same time, we are making meaningful progress across our late-stage portfolio, including continu
- PRKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific ConferencesClinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia.Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. The ABCD PlatformTM, an evolution of Kodiak's ABC platform to include conjugation of small molecules and other drugs, continues to advance as a versatile system for targeted, multi
- SECSEC Form DEFA14A filed by Kodiak Sciences IncDEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)
- SECSEC Form DEF 14A filed by Kodiak Sciences IncDEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)
- INSIDERSEC Form 4 filed by Borgeson John A.4 - Kodiak Sciences Inc. (0001468748) (Issuer)
KOD FAQ
7 questionsWhat does Kodiak Sciences Inc do?
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific...Where does KOD stock trade?
Kodiak Sciences Inc (KOD) is listed on NASDAQ.What sector and industry is KOD in?
Kodiak Sciences Inc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kodiak Sciences Inc go public?
Kodiak Sciences Inc (KOD) completed its IPO in 2018.What are analysts saying about KOD?
Kodiak Sciences Inc has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Buy on 2026-05-11.What companies are similar to KOD?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KOD side-by-side with any of them on Quantisnow.How can I track KOD on Quantisnow?
Quantisnow aggregates Kodiak Sciences Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KOD to receive live email and push alerts on every new disclosure.